GlassScriptPhysician profile
Sarah Lechanski
NPI 1013166651
$3,113.14
in general payments reported to CMS, 2019-2025
16 companies · $886 in 2025
The $886 reported for 2025 was more than what 89% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $323 · 2020: $188 · 2021: $69.93 · 2022: $347 · 2023: $534 · 2024: $765 · 2025: $886.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,186.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,185.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Vision Care, INC. | $793.59 | 2019-2025 | Acuvue |
| Alcon Vision LLC | $506.70 | 2019-2025 | Tryptyr, Eysuvis, Dailies Total1 |
| Glaukos Corporation | $470.06 | 2023-2025 | Kxl1b-Ce-Marked Kxlsystem, Kxl System (Not Refurbished), Photrexa Viscous and Photrexa |
| Bausch & Lomb Americas INC. | $449.91 | 2022-2025 | Infuse, Biotrue, Vyzulta |
| Tarsus Pharmaceuticals, INC. | $203.98 | 2024-2025 | Xdemvy |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $167.45 | 2019-2020 | |
| Dompe US, INC. | $124.99 | 2024 | Oxervate |
| Sun Pharmaceutical Industries INC. | $123.59 | 2023-2025 | Cequa |
| Coopervision INC. | $91.97 | 2019-2025 | Misight Contact Lens |
| Novartis Pharmaceuticals Corporation | $43.80 | 2022 | |
| Abb Con-Cise Optical Group LLC | $35.93 | 2025 | Contact Lens, Spectacle Lenses |
| Oyster Point Pharma, INC. | $26.37 | 2023 | Tyrvaya |
| Rxsight INC | $21.96 | 2022 | |
| Sight Sciences, INC. | $18.32 | 2022 | |
| Thea Pharma INC. | $17.95 | 2024 | Iyuzeh |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotissue Holdings INC. | $16.57 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Lechanski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.